Listar por tema 

Listar por tema "bulevirtide"

Mostrando ítems 1-4 de 4

    • Advances in hepatitis B therapeutics 

      Soriano, Vicente ; Barreiro, Pablo; Cachay, Edward R.; Kottilil, Shyamasundaran; Fernandez-Montero, José V.; Mendoza, Carmen de (Therapeutic Advances in Infectious Disease, 10/2020)
      Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of ...

    • Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy 

      Soriano, Vicente; Moreno-Torres, Víctor; Treviño, Ana; Corral, Octavio Jorge; de Mendoza, Carmen (Drug Design, Development and Therapy, 2023)
      It has been ten years since the identification of NTCP as the cell surface receptor for HBV and HDV entry into hepatocytes. The search for molecules interfering with the binding of NTCP and HBV/HDV led to design bulevirtide ...

    • Envisioning a hepatitis delta cure with new antivirals 

      Soriano, Vicente ; Mendoza, Carmen de; Barreiro, Pablo; Treviño, Ana ; Corral, Octavio Jorge (Future Medicine Ltd., 2021)
      Envisioning a hepatitis delta cure with new antivirals

    • Treatment of hepatitis delta and HIV infection 

      Soriano, Vicente; de Mendoza, Carmen; Treviño, Ana; Ramos-Rincón, José-Manuel; Moreno-Torres, Víctor; Corral, Octavio Jorge; Barreiro, Pablo (Liver International, 2023)
      Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5–10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15–25 million ...